title: VAD for remission induction as a first line and in relapsed adult acute lymphoblastic leukemia (ALL).
authors.affiliation: 1st Department of Propedeutic Medicine, Laikon Hospital Goudi Athens, Greece.
authors.forename: E
authors.initials: E
authors.lastname: Xefteri
authors.forename: A
authors.initials: A
authors.lastname: Polyzos
authors.forename: L
authors.initials: L
authors.lastname: Tzianoumis
authors.forename: M
authors.initials: M
authors.lastname: Tiniakoy
authors.forename: H
authors.initials: H
authors.lastname: Goumakou
authors.forename: E
authors.initials: E
authors.lastname: Pagalou
authors.forename: K
authors.initials: K
authors.lastname: Kotsis
authors.forename: P
authors.initials: P
authors.lastname: Sfikakis
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction
chemical_list: D005047:Etoposide; D004317:Doxorubicin